The table below shows Edgewise Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$143.82M
-$109.03M
-$91.95M
-$52.63M
-$33.51M
-$14.63M
Capital expenditure
$256.00K
$1.31M
$5.75M
$5.55M
$668.00K
$203.00K
Investing cash flow
-$32.79M
-$184.66M
$102.89M
-$70.58M
-$242.23M
-$24.38M
Dividends paid
-
-
-
-
EWTX operating cash flow (10-K history)
Edgewise Therapeutics, Inc. reported operating cash flow of -$143.82M for fiscal year 2025. That is down 31.9% from -$109.03M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$14.63M (FY 2020) to -$143.82M. Figures come from the company's audited annual reports as filed with the SEC.